Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASH 2012

8 - 11 Dec 2012

Massachusetts, Boston, United States of America

Clofarabine and other novel agents in AML; interview with Alan Burnett at ASH 2012

Prof Alan Burnett - Head of Haematology Department of Medical Genetics, Cardiff, Wales

Clofarabine and other novel agents in AML; interview with Alan Burnett at ASH 2012 ( Prof Alan Burnett - Head of Haematology Department of Medical Genetics, Cardiff, Wales )

Advances in multiple myeloma from ASH 2012

Prof Thierry Facon - Centre Hospitalier Universitaire, France

Advances in multiple myeloma from ASH 2012 ( Prof Thierry Facon - Centre Hospitalier Universitaire, France )

Expert overview of hot news in lymphoma from ASH 2012 (2/2)

Prof John Gribben, Prof Myron Czuczman, Prof Wolfram Brugger

Expert overview of hot news in lymphoma from ASH 2012 (2/2) ( Prof John Gribben, Prof Myron Czuczman, Prof Wolfram Brugger )

Expert overview of hot news in lymphoma from ASH 2012 (1/2)

Prof John Gribben, Prof Myron Czuczman, Prof Wolfram Brugger

Expert overview of hot news in lymphoma from ASH 2012 (1/2) ( Prof John Gribben, Prof Myron Czuczman, Prof Wolfram Brugger )

Advances in treatments for haematologic malignancies from the Sarah Cannon Research Institute presented at ASH 2012 (5/5)

Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA

Advances in treatments for haematologic malignancies from the Sarah Cannon Research Institute presented at ASH 2012 (5/5) ( Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA )

Advances in treatments for haematologic malignancies from the Sarah Cannon Research Institute presented at ASH 2012 (4/5)

Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA

Advances in treatments for haematologic malignancies from the Sarah Cannon Research Institute presented at ASH 2012 (4/5) ( Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA )

Advances in treatments for haematologic malignancies from the Sarah Cannon Research Institute presented at ASH 2012 (3/5)

Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA

Advances in treatments for haematologic malignancies from the Sarah Cannon Research Institute presented at ASH 2012 (3/5) ( Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA )

Advances in treatments for haematologic malignancies from the Sarah Cannon Research Institute presented at ASH 2012 (2/5)

Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA

Advances in treatments for haematologic malignancies from the Sarah Cannon Research Institute presented at ASH 2012 (2/5) ( Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA )

Advances in treatments for haematologic malignancies from the Sarah Cannon Research Institute presented at ASH 2012 (1/5)

Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA

Advances in treatments for haematologic malignancies from the Sarah Cannon Research Institute presented at ASH 2012 (1/5) ( Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA )

Multiple myeloma advances for the future suggested by phase I clinical research

Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA

Multiple myeloma advances for the future suggested by phase I clinical research ( Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA )

Advances in myeloid disease from ASH 2012 from the Sarah Cannon Research Institute

Dr Michael Savona - Sarah Cannon Research Institute, Nashville, USA

Advances in myeloid disease from ASH 2012 from the Sarah Cannon Research Institute ( Dr Michael Savona - Sarah Cannon Research Institute, Nashville, USA )

Highlights on multiple myeloma from ASH 2012

Professor Michel Delforge, Professor Meletios Dimopoulos

Highlights on multiple myeloma from ASH 2012 ( Professor Michel Delforge, Professor Meletios Dimopoulos )

Expert overview of CLL from ASH 2012

Professor John Gribben, Professor Peter Hillman, Professor Kanti Rai

Expert overview of CLL from ASH 2012 ( Professor John Gribben, Professor Peter Hillman, Professor Kanti Rai )

Expert overview of CLL in elderly from ASH 2012

Professor John Gribben, Professor Robin Foa, Professor Clemens Wendtner

Expert overview of CLL in elderly from ASH 2012 ( Professor John Gribben, Professor Robin Foa, Professor Clemens Wendtner )

Expert overview of hot news in multiple myeloma from ASH 2012

Professor Jesus San Miguel, Professor Faith Davies, Professor Antonio Palumbo

Expert overview of hot news in multiple myeloma from ASH 2012 ( Professor Jesus San Miguel, Professor Faith Davies, Professor Antonio Palumbo )

Advances in acute myeloid leukaemia (AML) for the elderly from ASH 2012

Professor Gert Ossenkoppele- VU University Medical Center, The Netherlands

Advances in acute myeloid leukaemia (AML) for the elderly from ASH 2012 ( Professor Gert Ossenkoppele- VU University Medical Center, The Netherlands )

Anaemia in patients receiving chemotherapy; where are we now?

Prof Matti Aapro - Clinique de Genolier in Genolier, Switzerland

Anaemia in patients receiving chemotherapy; where are we now? ( Prof Matti Aapro - Clinique de Genolier in Genolier, Switzerland )

Indolent lymphomas; advances from ASH 2012

Dr Mathias Rummel - Universitaetsklinik, Giessen, Germany

Indolent lymphomas; advances from ASH 2012 ( Dr Mathias Rummel - Universitaetsklinik, Giessen, Germany )

Overview of multiple myeloma with Maria Victoria Mateos

Dr Maria-Victoria Mateos - University Hospital of Salamanca, Spain

Overview of multiple myeloma with Maria Victoria Mateos ( Dr Maria-Victoria Mateos - University Hospital of Salamanca, Spain )

Advances and updates in treatments for myeloma presented at ASH 2012

Prof Keith Stewart - Mayo Clinic, Scottsdale, USA

Advances and updates in treatments for myeloma presented at ASH 2012 ( Prof Keith Stewart - Mayo Clinic, Scottsdale, USA )

Advances in myeloma at ASH 2012 (2/2)

Prof Gareth Morgan - The Royal Marsden Hospital, London

Advances in myeloma at ASH 2012 (2/2) ( Prof Gareth Morgan - The Royal Marsden Hospital, London )

Advances in myeloma at ASH 2012 (1/2)

Prof Gareth Morgan - The Royal Marsden Hospital, London

Advances in myeloma at ASH 2012 (1/2) ( Prof Gareth Morgan - The Royal Marsden Hospital, London )

Pre-Implantation genetic diagnosis

Dr Alison Lashwood - Guy's Hospital, London, UK

Pre-Implantation genetic diagnosis ( Dr Alison Lashwood - Guy's Hospital, London, UK )

The Childhood Cancer Survivor Study (CCSS) and the Women's Environmental Cancer and Radiation Epidemiology (WECARE) Study

Dr Chaya Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA

The Childhood Cancer Survivor Study (CCSS) and the Women's Environmental Cancer and Radiation Epidemiology (WECARE) Study ( Dr Chaya Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )

MLN9708 in combination with lenalidomide and dexamethasone against multiple myeloma

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

MLN9708 in combination with lenalidomide and dexamethasone against multiple myeloma ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )

PACE Trial: Phase II trial of ponatinib in patients with chronic myeloid leukaemia (CML)

Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA

PACE Trial: Phase II trial of ponatinib in patients with chronic myeloid leukaemia (CML) ( Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA )

Pomalidomide with low-dose vs. high-dose dexamathasone in refractory patients

Professor Meletios Dimopoulos - University of Athens, Greece

$Pomalidomide with low-dose vs. high-dose dexamathasone in refractory patients ( Professor Meletios Dimopoulos - University of Athens, Greece )$

MLN9708 in combination with lenalidomide and dexamethasone

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

MLN9708 in combination with lenalidomide and dexamethasone ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )

History of epidermal stem cell use in the clinical setting

Prof Michele De Luca - University of Modena e Reggio Emilia, Modena, Italy

History of epidermal stem cell use in the clinical setting ( Prof Michele De Luca - University of Modena e Reggio Emilia, Modena, Italy )

Exercise benefit to lifespan may be due to stem cell increase

Dr Mariusz Ratajczak - James Graham Brown Cancer Center, University of Louisville, Kentucky, USA

Exercise benefit to lifespan may be due to stem cell increase ( Dr Mariusz Ratajczak - James Graham Brown Cancer Center, University of Louisville, Kentucky, USA )

Histone deacetylases targeted as new strategy against graft versus host disease

Prof Sung Choi - University of Michigan, Ann Arbor, USA

Histone deacetylases targeted as new strategy against graft versus host disease ( Prof Sung Choi - University of Michigan, Ann Arbor, USA )

Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia

Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA

Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia ( Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA )

Quizartinib for FLT3-ITD positive AML after second-line chemo or stem cell transplant

Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA

Quizartinib for FLT3-ITD positive AML after second-line chemo or stem cell transplant ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )

The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab

Prof Jan Burger - The University of Texas MD Anderson Cancer Center, Houston, USA

The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab ( Prof Jan Burger - The University of Texas MD Anderson Cancer Center, Houston, USA )

Uncovering new targets for treatment of chronic lymphocytic leukaemia

Dr John Byrd - The Ohio State University Comprehensive Cancer Center, Columbus, USA

Uncovering new targets for treatment of chronic lymphocytic leukaemia ( Dr John Byrd - The Ohio State University Comprehensive Cancer Center, Columbus, USA )

More from ecancer